Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: A phase II study

Gynecologic Oncology

Volumn 60, Issue 1, 1996, Pages 59-63

  Pierga, J Y ^a   Dieras, V ^a   Paraiso, D ^a   Dorval, T ^a   Palangie, T ^a   Beuzeboc, P ^a   Jouve, M ^a   Scholl, S M ^a   Garcia Giralt, E ^a   Pouillart, P ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GESTAGEN;

ADVANCED CANCER; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SEPTICEMIA; TREATMENT OUTCOME;

EID: 0030069084     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0012     Document Type: Article

References (30)

1. Park, R. C., Grisby, P. W., Muss, H. B., and Norris, H. J. Corpus: Epithelial tumors, in Principles and practice of gynecologic oncology (W. J. Hoskins, C. A. Perez, and R. C. Young Eds.), Saunders, Philadelphia, pp. 663-693 (1992).
2. Creasman, W. T. Limited disease: Role of surgery, Semin. Oncol 21, 79-83 (1994).
3. Randall, M. E., and Reisinger, S. Radiation therapy and combined chemoirradiation in advanced and recurrent endometrial carcinoma, Semin. Oncol. 21, 91-99 (1994).
4. Neijt, J. P. Systemic treatment in disseminated endometrial cancer, Eur. J. Cancer 29A, 628-632 (1993).
5. Lentz, S. S. Advanced and recurrent endometrial carcinoma: Hormonal therapy, Semin. Oncol. 21, 100-106 (1994).
6. Muss, H. B. Chemotherapy of metastatic endometrial cancer, Semin. Oncol. 21, 107-113 (1994).
7. Moore, T. D., Phillips, P. H., Nerenstone, S. R., et al. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future prospects, J. Clin. Oncol. 9, 1071-1088 (1991).
8. DeVita, V. T., Wasserman, T. H., Young, R. C., and Carter, S. K. Perspectives on research in gynecologic oncology: Treatment protocols, Cancer 38, 509-525 (1976).
9. Durand, R. E., and Goldie, J. H. Interaction of etoposide and cisplatin in an in vitro tumor model, Cancer Treat. Rep. 71, 673-679 (1987).
10. Henwood, J. M., and Brogden, R. N. Etoposide: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in combination chemotherapy of cancer, Drugs 39, 438-490 (1990).
11. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations, J. Am. Stat. Assoc. 53, 457-481 (1958).
12. Thigpen, J. T., Blessing, J. A., DiSaia, P. J., Yordan, E., Carson, L. F., and Evers, C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study, J. Clin. Oncol. 12, 1408-1414 (1994).
13. Tropé, C., Grundsell, H., Johnsson, J. E., and Cavallin-Stahl, E. A phase II study of cis-platinum for recurrent corpus cancer, Eur. J. Cancer 16, 1025-1026 (1980).
14. Deppe, G., Cohen, C. J., Bruckner, H. W., et al. Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammineplatinum(II) after intensive prior therapy, Gynecol. Oncol. 10, 51-54 (1980).
15. Seski, J. C., Edwards, C. L., Herson, J., and Rutledge, F. N. Cisplatin chemotherapy for disseminated endometrial cancer, Obstet. Gynecol. 59, 225-(1982).
16. Thigpen, J. T., Blessing, J. A., Lagasse, L. D., DiSaia, P., and Homesley, H. D. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study, Am. J. Clin. Oncol. 7, 253-256 (1984).
17. Thigpen, J. T., Blessing, J. A., Homesley, H., Creasman, W. T., and Sutton, G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study, Gynecol. Oncol. 33, 68-70 (1989).
18. Deppe, G., Jacobs, A. J., Bruckner, H., and Cohen, C. J. Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil, and megestrol acetate, Am. J. Obstet. Gynecol. 140, 313-316 (1981).
19. Horton, J., Elson, P., Gordon, P., Hahn, R., and Creech, R. Combination chemotherapy for advanced endometrial cancer: An evaluation of three regimens, Cancer 49 (1982).
20. Cohen, C. J., Bruckner, H. W., Deppe, G., Blessing, J. A., Homesley, H., Lee, J. H., and Watring, W. Multidrug treatment of advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study, Obstet. Gynecol. 63, 719-726 (1984).
21. Piver, M. S., Lele, S. B., Pastner, B., and Emrich, L. J. Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma, Obstet. Gynecol. 67, 261-264 (1986).
22. Ayoub, J., Audet-Lapointe, P., Méthot, Y., Hanley, J., Beaulieu, R., Chemaly, R., Cormier, A., D́ery, J. P., Gauthier, P., Guay, J. P., Husson, D., Labrie, F., Lambert, B., Latreille, J., Mandevile, R., Michon, B., Pichet, R., Sidrac, S., Simard, A., Simard, P., Stanimir, P., Vauclair, R., and Vigeant, J. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status, Gynecol. Oncol. 31, 327-337 (1988).
23. O'Connel, M. J. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer, Cancer 63, 1026-1030 (1989).
24. Slayton, R. E., Blessing, J. A., and Delgado, G. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma, Cancer Treat. Rep. 66, 1669-1671 (1982).
25. O'Dwyer, P. J., Leyland-Jones, B., Alonso, M. T., Marsoni, S., and Wittes, R. E. Etoposide (VP-16-213). Current status of an active anti-cancer drug, N. Engl. J. Med. 312, 692-700 (1985).
26. Thigpen, J. T., Buchsbaum, H. J., Mangan, C., and Blessing, J. Phase II trial of Adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study, Cancer Treat. Rep. 63, 21-27 (1979).
27. Horton, J., Begg, C. B., Arseneault, J., Bruckner, H., Creech, R., and Hahn, R. G. Comparison of Adriamycin with cyclophosphamide in patients with advanced endometrial cancer, Cancer Treat. Rep. 62, 159-161 (1978).
28. Thigpen, J. T., Blessing, J., DiSaia, P., and Ehrlich, C. A randomized comparison of Adriamycin with or without cyclophosphamide in the treatment of advanced or recurrent endometrial cancer, Proc. Am. Soc. Clin. Oncol. 4, 115 (1985).
29. Thigpen, T., Blessing, J., Homesley, H., Malfetano, J., DiSaia, P., and Yordan, E. Phase III trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study, Proc. Am. Soc. Clin. Oncol. 12, 261 (1993).
30. Aapro, M., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., De Oliveira, C., Pawinski, A., Sahmoud, T., and Pecorelli, S. An EORTC - GCCG randomized phase II trial of doxorubicin (DOX) versus DOX - cisplatin (CDDP) in endometrial carcinoma, Proc. Am. Soc. Clin. Oncol. 13, 275 (1994).